PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Schott Pharma Schweiz Ag

USPTO PatentsView assignee record - 42 granted patents across 20 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ).

Explore the portfolio See the ranking
42
Total patents granted
20
CPC technology areas
17.3
Avg claims per patent
-
5-year grant velocity

The verdict

According to USPTO PatentsView, Schott ranks #7,769 of 50,000 tracked US assignees by granted-patent volume, with 42 patents across 20 technology areas.

#7,769
of 50,000 US assignees by volume
Top 4%
by Innovation Score (59.2/100)
17.3
avg claims per patent

Portfolio overview

Schott Pharma Schweiz Ag has been granted 42 US utility patents between 2023 and 2025, placing Schott Pharma Schweiz Ag at #7,769 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 20 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.3 claims per patent with primary concentration in A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ). As a Foreign Corporation, Schott Pharma Schweiz Ag is one of the more focused assignees in the PatentsView dataset. By volume, Schott sits between S.a. Lhoist Recherche Et Développement (42 patents, rank #7,763) and Shenzhen RELX Technology Co., Ltd. (42 patents, rank #7,771) - the closest US assignees by grant volume. The composite Innovation Score of 59.2/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Historical data spans 2023 through 2025, with 42 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Schott Pharma Schweiz Ag's 17.3 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 20 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Schott's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Schott holds 42 patents at rank #7,767, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Schott

By rank, the assignees closest to #7,767 in granted patent volume.

Leaders in A61J (Containers Specially Adapted FOR Medical OR Pharmaceutica…)

Other assignees with the most granted patents in Schott's primary technology class.

Schott's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

59 Top 4% higher than 96% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

510152025 202320242025 9
USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table
Schott Pharma Schweiz Ag patent grants by year, 2015–2025
Year Patents Granted Share of Period
2023 11 26.2%
2024 22 52.4%
2025partial year 9 21.4%

Which technologies does Schott Pharma Schweiz Ag patent most?

Top 15 of 20 technology areas

Grant record at a glance

Portfolio Volume 42 grants
CPC subclasses 20
Avg. claims / grant 17.3

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#7,769

of 50,000 tracked assignees

Innovation Score

59.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Schott Pharma Schweiz Ag rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Schott Pharma Schweiz Ag ranks #7,769 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Schott Pharma Schweiz Ag hold?
Schott Pharma Schweiz Ag holds 42 US utility patents granted between 2023 and 2025, spanning 20 technology areas.
What is Schott Pharma Schweiz Ag's Innovation Score?
Schott Pharma Schweiz Ag has an Innovation Score of 59.2 out of 100 (top 4% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Schott Pharma Schweiz Ag focus on?
Schott Pharma Schweiz Ag's top technology area is A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE) with 20 patents. Grants appear in 20 CPC subclasses total.
Is Schott Pharma Schweiz Ag's patent grant rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Schott Pharma Schweiz Ag.
What does claim depth mean for Schott Pharma Schweiz Ag's patents?
Schott Pharma Schweiz Ag's patents average 17.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Schott Pharma Schweiz Ag patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Schott's 42 grants land it in the top 4% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Schott ranks #7,769 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61J - see who else leads that technology area. A61J leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.